RxDoctor Payments Data

Richard Weise, MD

Ophthalmology · Glendale, CANPI 1285622662

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 84 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$481
  • Alcon$411
  • Eyevance Pharmaceuticals LLC$104
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$56
  • Novartis$43
  • Aerie Pharmaceuticals, Inc.$41
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$1,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,235 in reported general payments places this provider in the 45th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$974,827
Medicare patients
692
Services billed
5,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium305$117,124
VyzultaLatanoprostene Bunod170$61,076
CombiganBrimonidine Tartrate/Timolol91$28,687
RocklatanNetarsudil Mesylat/Latanoprost58$21,406
ZyletTobramycin/Lotepred Etab58$20,171
Bromfenac Sodium57$16,670
Bepotastine Besilate66$10,732
RhopressaNetarsudil Mesylate25$7,802
AlrexLoteprednol Etabonate21$7,434
LotemaxLoteprednol Etabonate17$5,863
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol40$4,015
LumiganBimatoprost11$3,834
Loteprednol Etabonate18$3,711
AzasiteAzithromycin13$3,152
Ketorolac Tromethamine124$3,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Zylet, Alrex, Lotemax, Loteprednol Etabonate$56$154,303419 claims
Bausch & Lomb Americas Inc.Vyzulta$481$61,076170 claims
AbbVieCombigan, Lumigan$17$32,520102 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$41$29,20883 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →